Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic … (NCT07562932) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock
South Korea512 participantsStarted 2026-05-31
Plain-language summary
The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are:
Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine?
Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest?
Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment.
Participants will:
Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug
Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock
Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization
Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment
This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.
Who can participate
Age range19 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age ≥ 19
✓. Cardiogenic shocka in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D
✓. systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \>90 mm Hg And
✓. Impaired cardiac function confirmed by cardiac catheterization or echocardiography
✓. SCAI B: no signs of hypoperfusion
✓. SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml/hour) or lactate over 2.0mmol/L
✓. SCAI D: requirement of second-line vasoactive drug or mechanical circulatory support based on the predefined treatment protocol
Exclusion criteria
✕. Administration of vasoactive drug more than 6 hours before enrollment
✕. Patients already on temporary mechanical circulatory supportb before enrollment
What they're measuring
1
A composite of 28-day all-cause death or signs of progressive or refractory cardiogenic shock within the first 24 hours